Global health organizations have announced a major collaboration to speed up the development of a vaccine against the Bundibugyo strain of Ebola, which is responsible for a worsening outbreak in the Democratic Republic of the Congo. The initiative brings together pharmaceutical company Merck, global health charity Wellcome through its joint venture Hilleman Laboratories, and CEPI, which is providing up to US$8.5 million in funding for the project.
The vaccine candidate is based on the same rVSV technology used in Merck's licensed Ervebo Ebola vaccine. Hilleman Laboratories plans to manufacture tens of thousands of doses for early-stage clinical trials by the end of the year, while Merck will contribute technical expertise and scientific support throughout the development process.
The urgency of the project reflects the severity of the current Ebola outbreak. According to health officials, thousands of infections and more than a thousand deaths have already been reported. In parallel with vaccine development, researchers are also evaluating several promising antiviral treatments to improve survival rates and strengthen outbreak response efforts.
Public health experts describe the collaboration as a significant step toward strengthening global preparedness against emerging infectious diseases. If clinical trials prove successful, the vaccine could become an important tool for containing future Ebola outbreaks and protecting vulnerable communities in Central Africa.
